1.05
price down icon2.78%   -0.03
after-market Handel nachbörslich: 1.04 -0.01 -0.95%
loading

Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten

pulisher
Jun 16, 2025

Jupiter Neurosciences’ Innovative Strategy in Biotech: A Dual Approach to Success - citybuzz -

Jun 16, 2025
pulisher
Jun 16, 2025

How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success - FinancialContent

Jun 16, 2025
pulisher
Jun 12, 2025

Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga

Jun 12, 2025
pulisher
Jun 09, 2025

Jupiter Neurosciences launches Nugevia longevity products By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Jupiter Neurosciences launches resveratrol-powered supplements - Longevity.Technology

Jun 09, 2025
pulisher
Jun 09, 2025

Pre-market Movers: KLTO, TPST, PYPD, MOVE... - RTTNews

Jun 09, 2025
pulisher
Jun 09, 2025

Jupiter Neurosciences launches Nugevia longevity products - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Jupiter Neurosciences Launches Nugevia™: A Premium - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Jupiter Neurosciences Targets $8T Longevity Market with Revolutionary 9x More Effective Supplement Line - Stock Titan

Jun 09, 2025
pulisher
Jun 02, 2025

IsoEnergy Announces Launch of At-The-Market Equity Program - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

Certain Restricted Stock Units of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com

May 31, 2025
pulisher
May 31, 2025

Certain Common Stock of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com

May 31, 2025
pulisher
May 31, 2025

Certain Options of Jupiter Neurosciences, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2025. - marketscreener.com

May 31, 2025
pulisher
May 20, 2025

Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews

May 20, 2025
pulisher
Apr 21, 2025

Jupiter Neurosciences appoints new auditor amid transition By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Jupiter Neurosciences appoints new auditor amid transition - Investing.com Australia

Apr 21, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson’s and longevity markets By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences Says Co Does Not Anticipate Impact From U.S. Tariffs On Clinical-Stage Prescription Product Development - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter Neurosciences targets Parkinson's and longevity markets - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Jupiter's Super-Resveratrol Targets Parkinson's Trial and $16.5M NIH Grant - Stock Titan

Apr 08, 2025
pulisher
Mar 28, 2025

Jupiter Neurosciences Inc. (JUNS) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 26, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price By Investing.com - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Jupiter Neurosciences faces NASDAQ delisting over share price - Investing.com

Mar 25, 2025
pulisher
Mar 18, 2025

Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma

Mar 18, 2025
pulisher
Mar 07, 2025

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Bluefield Daily Telegraph

Mar 07, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences and Aquanova AG Announce Strategic - GlobeNewswire

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences, Aquanova announce strategic collaboration - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences And Aquanova AG Announce Strategic Collaboration To Develop Longevity And Healthspan Products - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Jupiter Neurosciences partners with Aquanova on health products - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

Can Jupiter Neurosciences Capture The $44B Longevity Market With Its New Aquanova Partnership? - StockTitan

Mar 04, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences Inc (JUNS) Shares Decline Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Jupiter Neurosciences partners with Catalent for Parkinson’s trial By Investing.com - Investing.com Nigeria

Feb 10, 2025
pulisher
Feb 07, 2025

Three technology stocks with differentiated value propositions | 2025-02-07 | Investing News - Stockhouse Publishing

Feb 07, 2025
pulisher
Feb 07, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Feb 07, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences says volatility ‘appears to be driven by misconceptions’ - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - TradingView

Feb 04, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa

Feb 03, 2025
pulisher
Feb 03, 2025

Clinical Trials News Live Feed - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Phase 2a trial of Jotrol as treatment for Parkinson’s planned - Parkinson's News Today

Feb 03, 2025
pulisher
Jan 31, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial - Investing.com India

Jan 31, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study - Marketscreener.com

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial - GlobeNewswire

Jan 30, 2025
pulisher
Jan 30, 2025

Jupiter Neurosciences partners with Zina for Parkinson's trial By Investing.com - Investing.com South Africa

Jan 30, 2025
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Kapitalisierung:     |  Volumen (24h):